The University of Texas System

Vanderbilt University

Conocophillips Company

Navire Pharma, Inc.

Jason P Burke

Philip Jones

Michael J Soth

Kang Le

Gang Liu

Matthew Michael Hamilton

Timothy P Heffernan

Zhijun Kang

Maria Emilia Di Francesco

Christopher Lawrence Carroll

Barbara Czako

Timothy Joseph McAfoos

Richard T Lewis

Jay Theroff

Zachary Herrera

Anne Yau

Wylie S Palmer

Richard Thomas Lewis

Taekyu Lee

Stephen W Fesik

Alessia Petrocchi

Edward T Olejniczak

Naphtali Reyna

Johannes Belmar

Michelle Han

Jason Cross

Kwangho Kim

Plamen P Christov

Matthew White

John G Eller

Timothy Mcafoos

Zhiguo Bian

Michael P Soth

Gravity driven reverse circulator tools are provided and methods of using same. One tool has nested pipes that when fully nested close a hole in one of the pipes, but when the drillstring is lifted, the pipes partially separate under the force of gravity to expose the hole. The other embodiment is similar, but the hole is hook shaped (hook on top as in a walking cane) and a protrusion from the other pipe fits in the hole. Thus, both lifting and rotation are needed open the tool.

Reverse circulator and method

Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

Disclosed are systems and methods for pressure testing coiled tubing (CT) in a well. A CT pressure testing device may include a CT connector for attaching to a CT segment and a pressure test housing defining a pressure chamber. A rod may extend through a top opening of the pressure test housing and through the CT connector to the severed end of the CT segment. A sealing plug coupled to a bottom end of the rod may create an interface between the CT connector and the CT segment. A force activator may apply a force to a top end of the rod, causing the rod to push the sealing plug into the CT segment and tighten the interface. A pump may pressurize the pressure chamber to perform a pressure test on the sealing plug. Accordingly, the CT pressure testing device may establish a well control barrier for the well.

Systems and methods of pressure testing coiled tubing

Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

GLS1 inhibitors for treating disease

The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.

Substituted heterocyclic inhibitors of PTPN11

Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide

Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

Substituted indole Mcl-1 inhibitors

Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide

Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I:  Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide

Growing community of inventors

Houston, TX, United States of America

Jason P Burke